Novel findings underscore promise of H3 Biomedicine’s first-in-class splicing factor modulator H3B-8800 currently in Phase 1 clinical trial for patients with hematologic cancers and splicing factor...
Read More »Novel findings underscore promise of H3 Biomedicine’s first-in-class splicing factor modulator H3B-8800 currently in Phase 1 clinical trial for patients with hematologic cancers and splicing factor...
Read More »